Effect of a 1-month methotrexate delay on pneumococcal vaccine immunogenicity and disease control in patients with early rheumatoid arthritis (VACIMRA): an open-label randomised trial.

Saved in:
Bibliographic Details
Title: Effect of a 1-month methotrexate delay on pneumococcal vaccine immunogenicity and disease control in patients with early rheumatoid arthritis (VACIMRA): an open-label randomised trial.
Authors: Morel J; Department of Rheumatology, CHU Montpellier, University of Montpellier, Montpellier, France; PhyMedExp, INSERM U1046, CNRS, UMR 9214, CHRU de Montpellier, University of Montpellier, Montpellier, France. Electronic address: j-morel@chu-montpellier.fr., Dernis E; Department of Rheumatology, Community Hospital, Le Mans, France., Roux C; Department of Rheumatology, CHU de Nice and University Cote d'Azur, Nice, France., Richez C; Department of Rheumatology, CHU Bordeaux, Bordeaux, France; ImmunoConcEpT, CNRS UMR 5164, University of Bordeaux, Bordeaux, France., Brocq O; Department of Rheumatology, CHPG Monaco, Monaco., Fautrel B; Department of Rheumatology, Pitié-Salpêtrière Hospital Assistance-Publique Hôpitaux de Paris (AP-HP), CRI-IMIDIATE Clinical Research Network, INSERM U1136-5, Sorbonne Université, Paris, France., Salliot C; Rheumatology Unit, Orleans University Hospital, Orleans, France; Li2RSO, Orleans University, Orleans, France., Vittecoq O; Department of Rheumatology and CIC-CRB 1404, CHU Rouen, University Rouen Normandie, F-76000, Rouen, France., Mariette X; Department of Rheumatology, Hôpital Bicêtre, AP-HP, Université Paris-Saclay, Paris, France., Lioté F; Université Paris Cité and Bioscar, INSERM UMR 1132 and Services de rheumatologie, Institut Arthur Vernes and GH Paris Saint Jospeh, Paris, France., Lassoued S; Department of Rheumatology, Centre Hospitalier Jean-Rougié Cahors, Cahors, France., Gaujoux-Viala C; Department of Rheumatology, Niîmes University Hospital, Niîmes, France., Constantin A; Department of Rheumatology, Pierre-Paul Riquet University Hospital, Toulouse, France; INFINITY, INSERM UMR 1291, Purpan University Hospital, Toulouse University, Toulouse, France., Soubrier M; Department of Rheumatology, University Hospital of Clermont-Ferrand, Clermont-Ferrand, France., Devauchelle-Pensec V; Department of Rheumatology, Brest University Hospital, Brest, France., Goeb V; Department of Rheumatology, Centre Hospitalier Universitaire Amiens Picardie, Amiens, France., Gottenberg JE; Department of Rheumatology, Strasbourg University Hospitals, Strasbourg, France; National Reference Center for Rare Systemic Autoimmune Diseases, IBMC UPR 3572, University of Strasbourg, Strasbourg, France., Marotte H; Department of Rheumatology, Université Jean Monnet, CHU Saint-Etienne, Mines Saint-Etienne, INSERM 1059, Saint-Étienne, France., Moulard AR; Department of Rheumatology, CHU Montpellier, University of Montpellier, Montpellier, France., Daien C; Department of Rheumatology, CHU Montpellier, University of Montpellier, Montpellier, France; PhyMedExp, INSERM U1046, CNRS, UMR 9214, CHRU de Montpellier, University of Montpellier, Montpellier, France., Mouterde G; Department of Rheumatology, CHU Montpellier, University of Montpellier, Montpellier, France., Lukas C; Department of Rheumatology, CHU Montpellier, University of Montpellier, Montpellier, France., Pissarra J; Clinical Research and Epidemiology Unit, CHU Montpellier, University of Montpellier, Montpellier, France., Huguet H; Clinical Research and Epidemiology Unit, CHU Montpellier, University of Montpellier, Montpellier, France., Launay O; Université Paris Cité, CIC 1417, F-CRIN I-REIVAC, INSERM, Paris, France; Centre d'Investigation Clinique de Vaccinologie Cochin-Pasteur, Hôpital Cochin, AP-HP, Paris, France., Galtier F; Clinical Investigation Centre 1411, INSERM, CHU Montpellier, University of Montpellier, Montpellier, France., Picot MC; Clinical Research and Epidemiology Unit, CHU Montpellier, University of Montpellier, Montpellier, France; Clinical Investigation Centre 1411, INSERM, CHU Montpellier, University of Montpellier, Montpellier, France.
Corporate Authors: I-REIVAC, CRI-IMIDIATE French Clinical Research Networks
Source: The Lancet. Rheumatology [Lancet Rheumatol] 2025 Oct; Vol. 7 (10), pp. e675-e686. Date of Electronic Publication: 2025 Jul 29.
Publication Type: Journal Article; Randomized Controlled Trial; Multicenter Study
Journal Info: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101765308 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2665-9913 (Electronic) Linking ISSN: 26659913 NLM ISO Abbreviation: Lancet Rheumatol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2665-9913
DOI:10.1016/S2665-9913(25)00071-2